Announcements Trials
Browse Landscape

Status

Completed 8Active not recruiting 3Recruiting 2Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 566Neoplasms 463Lung Neoplasms 295Colorectal Neoplasms 291Carcinoma, Non-Small-Cell Lung 213Stomach Neoplasms 209Carcinoma, Hepatocellular 201Prostatic Neoplasms 181Pancreatic Neoplasms 151Ovarian Neoplasms 138Uterine Cervical Neoplasms 126Colonic Neoplasms 121Rectal Neoplasms 113Urinary Bladder Neoplasms 96Neoplasm Metastasis 95Esophageal Neoplasms 85Endometrial Neoplasms 83Head and Neck Neoplasms 80Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Leukemia, Myeloid, Acute 78Recurrence 68Brain Neoplasms 68Melanoma 66Disease 64Multiple Myeloma 59Liver Neoplasms 58Lymphoma 57Glioma 56Polycystic Ovary Syndrome 53Squamous Cell Carcinoma of Head and Neck 51

Interventions

delta 24-sterol reductase 1Pilot Projects 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Observational × Patient Preference × Clear all
NCT05236218 2023-03-08

To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).

King's College London

Unknown
60 enrolled

Patient Satisfaction, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡